In Phase 2 clinical trials, the safety profile was broadly consistent with other incretin-based therapies, with gastrointestinal side effects being the most commonly reported
Consequently, additional investigations elucidating the underlying mechanisms are imperative to confirm the effectiveness of ghrelin as a treatment target in FD
Contm aminocidos de alta pureza e absoro rpida
Chaveroux C, Sarcinelli C, Barbet V, Belfeki S, Barthelaix A, Ferraro-Peyret C, et al
Without adequate B12, these pathways slow down, and metabolic intermediates accumulate
Importantly, patients receiving concurrent SGLT2i therapy experienced even greater renoprotection, with a 58% reduction in kidney composite outcome risk (HR 0.42) (208)